Revista Clínica Española (English Edition) Revista Clínica Española (English Edition)
Rev Clin Esp 2018;218:298-304 - Vol. 218 Num.6 DOI: 10.1016/j.rceng.2018.02.010
Review
Use of tocilizumab in systemic sclerosis: A brief literature review
Utilización de tocilizumab en la esclerosis sistémica: breve revisión de la literatura
A. Fernández-Codinaa,b,, , J. Fernández-Fernándezc, A. Fernández-Pantigad, on behalf VII Master's final workgroup on the Clinical Management of Systemic Autoimmune Diseases of the Spanish Society of Internal Medicine 1
a Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitari Vall d’Hebron, Barcelona, Spain
b Rheumatology Division, Department of Medicine, University of Western Ontario, London, ON, Canada
c Servicio de Medicina Interna, Hospital de Mataró, Mataró, Spain
d Servicio de Medicina Interna, Hospital Universitario Central de Asturias, Oviedo, Spain
Received 23 December 2017, Accepted 17 February 2018
Abstract

The available treatments for systemic sclerosis (SS) have limited effectiveness. Treatment with tocilizumab (TCZ), a biological drug that inhibits interleukin 6 (IL-6), has recently been proposed. In this study, we conducted a literature review to assess the safety and efficacy of TCZ in SS. We found 52 articles, 10 of which we selected after evaluating the articles. In a randomized clinical trial, TCZ showed a nonsignificant improvement in the degree of skin induration, while another observational study showed neutral results. In this same clinical trial, the functional respiratory parameters showed a certain degree of stabilization. The safety profile of TCZ is acceptable; however, the current evidence regarding treatment of SS with TCZ is highly limited, although the drug could have a beneficial effect in skin disorder. New clinical trials are needed to determine the usefulness of TCZ in SS.

Resumen

Los tratamientos disponibles para la esclerosis sistémica (ES) tienen una efectividad limitada. Recientemente se ha propuesto el tratamiento con tocilizumab (TCZ), un fármaco biológico que inhibe la interleucina 6 (IL6). En este trabajo se realiza una revisión de la literatura para evaluar la eficacia y seguridad de TCZ en ES. Se han encontrado 52 artículos, de los que, tras su evaluación, se han seleccionado solo 10. En un ensayo clínico aleatorizado TCZ demostró una mejoría no significativa del grado de induración cutánea, mientras que en un estudio observacional los resultados fueron neutros. En dicho ensayo clínico, los parámetros funcionales respiratorios mostraron cierto grado de estabilización. El perfil de seguridad de TCZ es aceptable. La evidencia actual en cuanto al tratamiento de la ES con TCZ es muy limitada, aunque el fármaco podría tener un efecto beneficioso en la afectación cutánea. Se requieren nuevos ensayos clínicos para comprobar su utilidad en ES.

Keywords
Systemic sclerosis, Tocilizumab, Treatment
Palabras clave
Esclerosis sistémica, Tocilizumab, Tratamiento

Article

To access the full text of the publication Revista Clínica Española (English Edition) you need to be a subscriber or member of the Sociedad Española de Medicina Interna.

  • If you are a member of the Sociedad Española de Medicina Interna::
    1.- You must go to the following address http://www.fesemi.org/publicaciones/revista-clinica/ultimo/view
    2.- Authenticate as a member of the SEMI. You must use your login details
    3.- Access to the contents of Revista Clínica Española

  • If you are a subscriber:
    Can you recover your data in the "I Forgot my Password" button on the right sidebar of this website.

Rev Clin Esp 2018;218:298-304 - Vol. 218 Num.6 DOI: 10.1016/j.rceng.2018.02.010
Cookies Policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.